Immune checkpoint inhibitors (ICIs), as one of the innovative types of immunotherapies,
including programmed cell death-1 (PD-1), programmed cell death-ligand 1 (PD-L1), and …

The treatment of malignant tumors has entered the era of immunotherapy, and immune
checkpoint inhibitors (ICIs) have brought significant benefits to patients. However, some …

Importance Systemic steroids are commonly used to manage immune-related adverse
events (irAEs), but it remains unclear whether they may undermine immune checkpoint …

Background: Despite their anti-tumor efficacy, immune checkpoint inhibitors (ICIs) are
associated with a variety of immune-related adverse events (irAEs). Grade≥ 2 irAEs require …

The development of the immune checkpoint inhibitors (ICI) is one of the most remarkable
achievements in cancer therapy in recent years. However, their exponential use has led to …

Takotsubo syndrome (TTS) is characterized by a transient left ventricular systolic
dysfunction, burdened by significant acute and long-term mortality and morbidity. The …

Background The implementation of patient-reported outcome measures (PROMs) in the
clinical identification of immunotherapy toxicities is a complex intervention. There has been …

Objective The correlation between immune-related adverse events (irAEs) and prognosis
remains controversial in advanced non–small cell lung cancer (NSCLC). The aim of this …

Immune checkpoint inhibitors (ICIs) are monoclonal antibodies that activate the immune
system, aiming at enhancing antitumor immunity. ICIs have shown great promise in the …

Backgrounds There is little evidence on the safety, efficacy, and survival benefit of restarting
immune checkpoint inhibitors (ICI) in patients with cancer after discontinuation due to …